However, recent findings indicate that due to its potent anti-inflammatory characteristics, it exhibits immunomodulatory effects in chronic cardiovascular inflammation models, reducing circulating TNF-α levels, and is thus considered a potential drug for inflammatory diseases (107).Canakinumab and Rilonacept are IL-1β antagonists. The gene discussed is TNF; the disease is inflammation.